Date: 2013-04-09
Type of information: Research agreement
Compound: clinical candidates targeting nuclear receptors
Company: NovAliX (France) Inventiva (France)
Therapeutic area:
Type agreement: research - development
Action mechanism:
Disease:
Details:
- Inventiva and NovAliX have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors. After several years of successful collaboration in the field of nuclear receptors and a proven track record with three programs having reached clinical stage, Inventiva and NovAliX are now officially teaming up to establish a solid alliance to further deliver on the therapeutic promises of the nuclear receptor target class.
Through this alliance, Inventiva and NovAliX offer pharmaceutical and biotech companies a unique set of fully integrated nuclear receptor drug discovery capabilities by combining their respective in-depth expertise in structural biology, medicinal chemistry, biology, DMPK, pharmacology and safety. This alliance will leverage Inventiva’s and NovAliX’s diversified proprietary libraries in combination with complementary screening technologies (multiple biophysical techniques combined with biochemical and bio-functional assays).
Financial terms:
Latest news:
Is general: Yes
